Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Surmodics (SRDX)
NASDAQ:SRDX
SurModics (SRDX) Stock Price & Analysis
111 Followers
SRDX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.17 - $42.44
Previous Close$41.97
Volume472.88K
Average Volume (3M)327.11K
Market Cap
$601.57M
Enterprise Value$587.26M
Total Cash (Recent Filing)$40.94M
Total Debt (Recent Filing)$29.48M
Price to Earnings (P/E)43.9
Beta1.30
Next Earnings
Jul 31, 2024EPS Estimate
-$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.96
Shares Outstanding14,260,000
10 Day Avg. Volume311,866
30 Day Avg. Volume327,114
Standard Deviation0.16
R-Squared0.15
Alpha-0.00369
Financial Highlights & Ratios
Price to Book (P/B)10.76
Price to Sales (P/S)4.51
Price to Cash Flow (P/CF)20.20
P/FCF Ratio21.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.71
Enterprise Value/Gross Profit9.62
Enterprise Value/Ebitda18.11
Forecast
1Y Price Target
$43.00Price Target Upside2.45% Upside
Rating ConsensusHold
Number of Analyst Covering4
SurModics News
PremiumCompany Announcements
SurModics Incentivizes Executives Ahead of MergerBulls Say, Bears Say
Bulls Say
AcquisitionSurmodics is being acquired by GTCR for $43.00/share in cash, representing a 41% premium to its 30-trading day volume-weighted average closing price.
Financial PerformanceQ2 financial results were much better than expected and included $32.0 million in revenue and $0.07 in non-GAAP EPS.
Product DevelopmentThe momentum of new products like SurVeil, Pounce, and Sublime is the clear catalyst behind the increased top-line guidance for FY/24.
Bears Say
Management CommunicationManagement has chosen to enter a quiet period and is not engaging with analysts or investors on the advice of counsel.
Revenue GrowthRevenue growth slowed to 19% in F2Q24 from 25% in F1Q24.
Valuation And OffersThe deal fairly values SRDX and no higher offer is expected.
---
Ownership Overview
51.17% Insiders
20.29% Mutual Funds
12.16% Other Institutional Investors
16.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SRDX FAQ
What was Surmodics’s price range in the past 12 months?
Surmodics lowest stock price was $25.17 and its highest was $42.44 in the past 12 months.
What is Surmodics’s market cap?
Currently, no data Available
When is Surmodics’s upcoming earnings report date?
Surmodics’s upcoming earnings report date is Jul 31, 2024 which is in 5 days.
How were Surmodics’s earnings last quarter?
Surmodics released its earnings results on May 01, 2024. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of -$0.35 by $0.42.
Is Surmodics overvalued?
According to Wall Street analysts Surmodics’s price is currently Undervalued.
Does Surmodics pay dividends?
Surmodics does not currently pay dividends.
What is Surmodics’s EPS estimate?
Surmodics’s EPS estimate is -$0.34.
How many shares outstanding does Surmodics have?
Surmodics has 14,265,435 shares outstanding.
What happened to Surmodics’s price movement after its last earnings report?
Surmodics reported an EPS of $0.07 in its last earnings report, beating expectations of -$0.35. Following the earnings report the stock price went up 29.739%.
Which hedge fund is a major shareholder of Surmodics?
Among the largest hedge funds holding Surmodics’s share is Royce & Associates LLC. It holds Surmodics’s shares valued at 12M.
---
SurModics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$43.00 (2.45% Upside)
$43.00 (2.45% Upside)
Blogger Sentiment
Bullish
SRDX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.4K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.61%
12-Months-Change
Fundamentals
Return on Equity
11.92%
Trailing 12-Months
Asset Growth
10.02%
Trailing 12-Months
Company Description
Surmodics
SurModics, Inc. engages in the provision of medical device and in vitro diagnostic technologies to the healthcare industry. It operates through the Medical Device and In Vitro Diagnostics segments. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment consists of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.
---
SRDX Earnings Call
Q2 2024
0:00 / 0:00
---
SRDX Stock 12 Month Forecast
Average Price Target
$43.00
▲(2.45% Upside)
Technical Analysis
---